First patient dosed in Ph 1 trial of ABSK211 for advanced solid tumors with KRAS alterations
Abbisko Therapeutics has begun first patient dosing in a Phase I trial of ABSK211, an oral pan-KRAS inhibitor for advanced solid tumors with KRAS alterations. Preclinical data show broad, durable anti-tumor activity and combination potential for ABSK211, highlighting Abbisko’s global oncology ambitions despite inherent early-stage biotech risks.
Share:
More News
Dr Jing He, Head of R&D China, AstraZeneca, said: “These positive data underscore the pivotal role of ORPATHYS® in intercepting MET-driven resistance early in the treatment journey. By combining the targeted precision of ORPATHYS® with backbone TAGRISSO®, SANOVO demonstrates a meaningful clinical advancement for treatment-naïve patients with MET overexpression and
“ADI-212 marks an important milestone in Adicet’s strategy to address the complexity of solid tumors and represents an important addition to our portfolio of allogeneic gamma delta 1 cell therapies and in vivo CAR T programs,” said Blake Aftab, Ph.D., Chief Scientific Officer of Adicet Bio. “Designed as a single
“Any decision concerning clinical trials is made with utmost care, keeping patients as our highest priority,” said Prof. Özlem Türeci, M.D., Co-Founder and Chief Medical Officer at BioNTech. “While this outcome is not what we had envisioned for mRNA as a monotherapy in colorectal cancer, it provides scientific insight into
“These results reinforce our confidence that Ziihera is the new HER2-targeted backbone therapy in first-line HER2+ advanced GEA, replacing trastuzumab and extending survival beyond the current standard of care,” said Rob Iannone, M.D., M.S.C.E., executive vice president, global head of research and development, and chief medical officer of Jazz Pharmaceuticals.